中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

益生菌对慢加急性肝衰竭大鼠模型的保护作用及其机制

张永超 毕研贞 方萧 王全义 王全全 唐慧昕 孔令斌 陈煜 段钟平 舒振锋 洪丰

引用本文:
Citation:

益生菌对慢加急性肝衰竭大鼠模型的保护作用及其机制

DOI: 10.3969/j.issn.1001-5256.2019.07.029
基金项目: 

国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治”(2017ZX10203201-005,2017ZX10202203-006-001,2017ZX10302201-004-002,2012ZX10002004-006,2017ZX10201201); 国家重点研发计划(2017YFA0103000); 国家自然科学基金(81170395,81570556); 

详细信息
  • 中图分类号: R575.3;R-332

Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism

Research funding: 

 

  • 摘要:

    目的探究益生菌干预对慢加急性肝衰竭(ACLF)大鼠的作用及其机制。方法采用随机数字表法将44只雄性SD大鼠随机分为6组,对照组1(C1组,n=6,不做任何干预)、模型组1(M1组,n=8,40%CCl4油溶液腹腔注射10周,从第7周开始每天灌胃PBS溶液,10周末给予D-GalN急性攻击)、益生菌干预组1(Y1组,n=8,造模同M1组,灌胃剂为益生菌溶液)、对照组2(C2组,n=6,不做任何干预)、模型组2(M2组,n=8,腹腔注射40%CCl4油溶液,10周后给予D-GalN急性攻击,48 h后每天灌胃PBS溶液,持续到第12周末处死)、益生菌干预组2(Y2组,n=8,造模同M2组,灌胃剂为益生菌溶液)。观察干预前后大鼠体质量、肝功能、肝组织病理学,采用ELISA法测血浆内毒素、肠道分泌型免疫球蛋白A(s IgA),Western Blot法测定肠道紧密连接蛋白occludin的水平,RT-PCR法检测肠道紧密连接蛋白occludin和ZO-1的mRNA水平,通过选择性培养基测定肠道菌群等指标的变化。计量资料多组间比较采用单因素方差分析,进一步两两比较采用SNK-q检验。结果 C1、...

     

  • [1]LALEMAN W, CLARIA J, van der MERWE S, et al.Systemic inflammation and acute-on-chronic liver failure:Too much, not enough[J].Can J Gastroenterol Hepatol, 2018, 2018:1027152.
    [2]CHEN Y, GUO J, QIAN G, et al.Gut dysbiosis in acute-onchronic liver failure and its predictive value for mortality[J].JGastroenterol Hepatol, 2015, 30 (9) :1429-1437.
    [3] MENG X, LI S, LI Y, et al.Gut microbiota's relationship with liver disease and role in hepatoprotection by dietary natural products and probiotics[J].Nutrients, 2018, 10 (10) :pii:e1457.
    [4]CHEN MX, WANG SY.Role of intestinal dysbacteriosis in the pathogenesis of acute-on-chronic hepatitis B liver failure[J].J Clin Hepatol, 2019, 35 (3) :665-668. (in Chinese) 陈木兴, 王少扬.肠道菌群失调在乙型肝炎相关慢加急性肝衰竭发病机制中的作用[J].临床肝胆病杂志, 2019, 35 (3) :665-668.
    [5]LU BJ, ZHAO YH, AN YT, et al.Research advances in gut microbiota in liver cirrhosis and related complications[J].JClin Hepatol, 2018, 34 (11) :2433-2437. (in Chinese) 鲁冰洁, 赵亚红, 安泳潼, 等.肠道微生物在肝硬化及相关并发症中的研究进展[J].临床肝胆病杂志, 2018, 34 (11) :2433-2437.
    [6]FUKUI H.Gut-liver axis in liver cirrhosis:How to manage leaky gut and endotoxemia[J].World J Hepatol, 2015, 7 (3) :425-442.
    [7] WOODHOUSE CA, PATEL VC, SINGANAYAGAM A.Review article:The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J].Aliment Pharmacol Ther, 2018, 47 (2) :192-202.
    [8] ARAB JP, MARTIN-MATEOS RM.Gut-liver axis, cirrhosis and portal hypertension:The chicken and the egg[J].Hepatol Int, 2018, 12 (Suppl 1) :24-33.
    [9]FIJAN S.Microorganisms with claimed probiotic properties:an overview of recent literature[J].Int J Environ Res Public Health, 2014, 11 (5) :4745-4767.
    [10] LI Y, LV L, YE J, et al.Bifidobacterium adolescentis CGMCC15058 alleviates liver injury, enhances the intestinal barrier and modifies the gut microbiota in D-galactosamine-treated rats[J].Appl Microbiol Biotechnol, 2019, 103 (1) :375-393.
    [11] ESLAMPARAST T, POUSTCHI H, ZAMANI F, et al.Synbiotic supplementation in nonalcoholic fatty liver disease:A randomized, double-blind, placebo-controlled pilot study[J].Am J Clin Nutr, 2014, 99 (3) :535-542.
    [12] FAMOURI F, SHARIAT Z, HASHEMIPOUR M, et al.Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents[J].Pediatr Gastroenterol Nutr, 2017, 64 (3) :413-417.
    [13] DELZENNE NM, KNUDSEN C, BEAUMONT M, et al.Contribution of the gut microbiota to the regulation of host metabolism and energy balance:A focus on the gut-liver axis[J].Proc Nutr Soc, 2019.[Epub ahead of print]
    [14] AMINLARI L, SHEKARFOROUSH SS, HOSSEINZADEH S, et al.Effect of probiotics bacillus coagulans and lactobacillus plantarum on lipid profile and feces bacteria of rats fed cholesterol-enriched diet[J].Probiotics Antimicrob Proteins, 2018.[Epub ahead of print]
    [15] LOMAN BR, HERNANDEZ-SAAVEDRA D, AN R.Prebiotic and probiotic treatment of nonalcoholic fatty liver disease:Asystematic review and meta-analysis[J].Nutr Rev, 2018, 76 (11) :822-839.
    [16]BELIZARIO JE, FAINTUCH J.Gut microbiome dysbiosis and immunometabolism:New frontiers for treatment of metabolic diseases[J].Mediators Inflamm, 2018, 2018:2037838.
    [17]OIKONOMOU T, PAPATHEODORIDIS GV, SAMARKOS M, et al.Clinical impact of microbiome in patients with decompensated cirrhosis[J].World J Gastroenterol, 2018, 24 (34) :3813-3820.
    [18] FUKUI H.Changes of intestinal functions in liver cirrhosis[J].Inflamm Intest Dis, 2016, 1 (1) :24-40.
    [19]ASSIMAKOPOULOS SF, TSAMANDAS AC, TSIAOUSSIS GI, et al.Altered intestinal tight junctions'expression in patients with liver cirrhosis:A pathogenetic mechanism of intestinal hyperpermeability[J].Eur J Clin Invest, 2012, 42 (4) :439-446.
    [20]YU W, LU B, ZHANG H, et al.Effects of the Sijunzi decoction on the immunological function in rats with dextran sulfate-induced ulcerative colitis[J].Biomed Rep, 2016, 5 (1) :83-86.
    [21]ASHRRF R.Immune system stimulation by probiotic microorganisms[J].Crit Rev Food Sci Nutr, 2014, 54 (7) :938-956.
  • 加载中
计量
  • 文章访问数:  1328
  • HTML全文浏览量:  29
  • PDF下载量:  278
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-18
  • 出版日期:  2019-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回